BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, October 31, 2024
Breaking News: Best of BioWorld Science: Q3
See today's BioWorld Science
Home
» Ribox’s RXRG-001 cleared to enter clinic for radiation-induced xerostomia and hyposalivation
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Ear, nose & throat
Ribox’s RXRG-001 cleared to enter clinic for radiation-induced xerostomia and hyposalivation
Oct. 28, 2024
No Comments
Ribox Therapeutics Ltd. has obtained IND clearance from the FDA for the company’s circular RNA therapy, RXRG-001.
BioWorld Science
Regulatory
Cancer
Ear, nose and throat
FDA
IND
